Bridge Biotherapeutics Announces the Initiation of the Proof of Mechanism Study for BBT-401 in Patients with Ulcerative Colitis; Rectal Delivery of Drug to Target Site
- The new proof of mechanism trial in ulcerative colitis had its first patient dosed in New Zealand
- In parallel with the oral-administered, proof of clinical principle study, the new proof of mechanism study will examine the efficacy of BBT-401 when delivered directly to the target organ via rectal administration
SEONGNAM, South Korea, June 2, 2021 /PR...